Sanofi (SNY) Stock Rating Reaffirmed by Nord/LB

Nord/LB reaffirmed their neutral rating on shares of Sanofi (NYSE:SNY) in a report issued on Wednesday, December 27th.

Other analysts also recently issued reports about the stock. Bank of America downgraded shares of Sanofi from a buy rating to a neutral rating in a research report on Wednesday, December 6th. Argus reaffirmed a buy rating and set a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. raised shares of Sanofi from a reduce rating to a hold rating in a report on Wednesday, August 30th. Barclays raised shares of Sanofi from an underweight rating to an equal weight rating in a report on Wednesday, November 15th. Finally, Cowen set a $48.00 price target on shares of Sanofi and gave the company a hold rating in a report on Monday, December 18th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. Sanofi presently has a consensus rating of Hold and a consensus target price of $51.50.

Shares of Sanofi (SNY) opened at $44.78 on Wednesday. Sanofi has a 1 year low of $39.42 and a 1 year high of $50.65. The company has a market cap of $111,790.00, a PE ratio of 20.64, a P/E/G ratio of 2.58 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fisher Asset Management LLC raised its stake in Sanofi by 3.3% during the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after acquiring an additional 443,799 shares during the period. Boston Partners raised its position in shares of Sanofi by 6.2% during the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock valued at $431,429,000 after buying an additional 503,799 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in shares of Sanofi by 0.7% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 5,863,945 shares of the company’s stock valued at $291,966,000 after buying an additional 38,597 shares during the last quarter. FMR LLC raised its position in shares of Sanofi by 3.0% during the second quarter. FMR LLC now owns 5,374,385 shares of the company’s stock valued at $257,487,000 after buying an additional 155,751 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Sanofi by 1.1% during the third quarter. Macquarie Group Ltd. now owns 2,622,391 shares of the company’s stock valued at $130,569,000 after buying an additional 29,045 shares during the last quarter. Institutional investors own 9.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2018/01/13/sanofi-sny-stock-rating-reaffirmed-by-nord-lb.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply